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Abstract
Chronic myelomonocytic leukaemia is an atypical myeloproliferative disorder with a natural history
of progression to acute myeloid leukaemia, a complex and poorly understood response by the
bone marrow to stress. Cardiac surgery activates many inflammatory cascades and may precipitate
a systemic inflammatory response syndrome. We present a case of undiagnosed chronic
myelomonocytic leukaemia who developed rapidly fatal multi-organ dysfunction following cardiac
surgery due to an acute leukaemoid reaction.
Background
Chronic myelomonocytic leukaemia (CMML) is an atypi-
cal myeloproliferative disorder characterized by an abso-
lute peripheral blood monocyte count of greater than 1.0
× 109/L, with evidence of both effective and ineffective
haematopoiesis [1]. The aetiology of CMML is complex
and incompletely understood. It is twice as common in
men, usually presenting in the seventh or eighth decades.
Late clinical features include fatigue, weight loss, fever and
night sweats, splenomegaly and hepatomegaly, although
it may present as a chance finding on blood analysis. The
bone marrow is usually hypercellular with granulocytic
proliferation and it can be differentiated from classical
chronic myeloid leukaemia by the high monocyte count
and absence of a Philadelphia chromosome. Despite best
medical therapy, the outcome remains poor with median
survival less than two years from the time of diagnosis.
Individual prognosis is difficult to predict, although
approximately 20% of patients progress to acute myeloid
leukaemia [2].
Cardiac surgery has been reported in patients with chronic
lymphocytic leukaemia, myelodysplasia and other malig-
nant haematological disorders [3-5] but data on CMML
are limited [6]. We present a case of previously undiag-
nosed CMML who developed fatal complications follow-
ing cardiac surgery.
Case report
A 70-year-old man was referred for coronary revasculari-
zation with angina (Canadian Cardiovascular Society
class 2), three vessel disease and good left ventricular
function. He was otherwise well, with no significant past
medical history and physical examination was unremark-
able. Preoperative risk assessment scores were: Euro-
SCORE standard 3 (age), logistic 1.82. Preoperative
investigations revealed a white cell count (WCC) of 15.6
× 109/L (neutrophils 10.1 × 109/L, monocytes 2.5 × 109/
L) and urinalysis positive for blood. He denied any uri-
nary or respiratory symptoms but was treated empirically
for a lower urinary tract infection and discharged home.
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Urine culture was negative. Two weeks later, the WCC
remained elevated at 14.2 × 109/L (neutrophils 10.5 ×
109/L, monocytes 1.6 × 109/L), although he remained
asymptomatic and was keen to proceed. 
Coronary artery bypass grafting was performed using the
left internal mammary artery and saphenous vein grafts.
Cardiopulmonary bypass (CPB) time was 76 minutes
with aortic cross-clamp for 39 minutes, using antegrade
cold crystalloid cardioplegia. The patient came off CPB
easily and remained haemodynamically stable thereafter.
He was extubated expeditiously and returned to the ward
on the first postoperative day. Routine blood tests demon-
strated a leukocytosis (46.9 × 109/L) with marked neu-
trophilia (38.5 × 109/L) and monocytosis (8.4 × 109/L).
Late on the first postoperative day, his condition deterio-
rated with progressive hypoxia, oliguria and metabolic
acidosis. He was readmitted to the intensive care unit for
non-invasive ventilation and inotropic support. On the
morning of the second postoperative day, he remained
hypoxic and oliguric. A pulmonary artery catheter
revealed low cardiac output state and low systemic vascu-
lar resistance. He was reintubated and mechanically ven-
tilated, inotropic therapy was increased and continuous
veno-venous haemofiltration and broad-spectrum antibi-
otics were commenced. A cardiac origin of low cardiac
output was excluded and sepsis or splanchnic ischemia
were considered as causes of his systemic inflammatory
response syndrome (SIRS) and multi-organ dysfunction
(MOD). Computed tomography of the thorax and abdo-
men showed bilateral ground glass shadowing of the lung
parenchyma consistent with acute respiratory distress syn-
drome but no other significant findings. The leukocytosis
increased to 91.7 × 109/L (neutrophils 54.1 × 109/L,
monocytes 33.0 × 109/L) and his condition deteriorated.
A haematology opinion was sought and confirmed a diag-
nosis of probable leukaemoid reaction on a background
of CMML. Despite maximal therapy, the patient died on
the third postoperative day. Post-mortem findings were of
an enlarged spleen and widespread SIRS, manifesting as
pulmonary congestion with patchy hemorrhagic necrosis
of the small and large bowel.
Discussion
Cardiac surgery produces an altered activation of the
inflammatory response due to the combination of surgi-
cal trauma, cardiopulmonary bypass and ischemia-reper-
fusion injury [7]. Marked amplification of this process can
result in SIRS. In CMML, some patients may progress to
the acute phase of myeloid leukaemia, a complex and
poorly understood response by the bone marrow to stress.
In this patient, it appears that the inflammatory storm
generated by cardiac surgery with CPB precipitated a dra-
matic myelomonocytic leukaemoid reaction, with a clini-
cal picture of SIRS and MOD. The pathways responsible
for this response are unknown.
The patient was referred for cardiac surgery with undiag-
nosed CMML. As the proportion of elderly patients under-
going surgery steadily increases, more occult chronic
conditions are likely to be diagnosed on preoperative
work-up. Despite reports that patients with chronic hae-
matological malignancies undergoing cardiac surgery are
at increased risk of complications, including bleeding and
infection [3], a preoperative diagnosis would not neces-
sarily have altered the decision to proceed with surgical
revascularization. In retrospect, the blood count and film
were suggestive of CMML in the chronic phase, with no
evidence of acute transformation or the leukaemoid reac-
tion to come. Indeed, urgent coronary artery surgery has
been successfully performed in a patient with acute mye-
loid leukaemia [8]. The key questions are whether patients
with haematological malignancies with a poor prognosis
should be candidates for cardiac surgery for prognostic
benefit  per se and why our patient responded to the
inflammatory stress of surgery in such a catastrophic and
unpredictable fashion. This may be related to the unfortu-
nate timing of surgery in the natural course of his disease
or the susceptibility of his particular subtype of CMML to
inflammatory stress.
Patients with CMML may benefit from a strategy aimed at
decreasing their exposure to inflammatory stimuli. Off-
pump coronary artery bypass (OPCAB) surgery avoids the
need for CPB but still causes significant surgical trauma.
Whilst recent studies suggest a decrease in the systemic
inflammatory response in OPCAB surgery, there may not
always be a direct correlation between measured inflam-
matory markers, pathophysiological consequences and
clinical outcome [7]. The only report of OPCAB in a
patient with CMML, performed via a median sternotomy,
highlighted concerns over leukaemoid transformation
and the assumed benefits of a reduction in cytokine
release [6].
In conclusion, patients with CMML are at increased risk
for cardiac surgery. The response to the inflammatory
stimulus of surgery is difficult to predict. A leukaemoid
reaction may prove rapidly fatal although the cause of dis-
ease acceleration and potential remitting factors remain
obscure. With better understanding of the inflammatory
response to surgery, cardiopulmonary bypass and bone
marrow homeostasis in chronic leukaemic conditions,
patient selection for surgery may be refined dependent on
CMML subtype risk assessment. As these patients may rep-
resent a group in whom the lowering of inflammatory
stress is particularly beneficial, OPCAB may have a spe-
cific role. Alternatively, cytokines such as interleukin-2
and interleukin-6 may present potential therapeutic tar-Publish with BioMed Central    and   every 
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gets for modulating the inflammatory response following
cardiac surgery in patients at risk.
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